The American Academy of Dermatology (AAD) is non-profit professional organization of dermatologists in the United States and Canada, based in Rosemont, Illinois, near Chicago. It was founded in 1938 and has more than 20,500 members. The academy grants fellowships and associate memberships, as well as fellowships for nonresidents of the United States or Canada. Since 1979, the AAD also publishes a monthly medical journal, the Journal of the American Academy of Dermatology.To become a Fellow of the American Academy of Dermatology (FAAD), a physician must be a resident of the United States of America or Canada and certified by the American Board of Dermatology or in dermatology by the Royal College of Physicians and Surgeons of Canada.To become an associate member, a physician must have three years of experience in practice or as a teacher or graduate student of dermatology and must have had training that qualifies for examination by the American Board of Dermatology or the Royal College of Physicians and Surgeons of Canada.
Background Pediatric atopic dermatitis (AD) is a common, chronic inflammatory skin disorder that significantly impacts the quality of life of affected children and their families. Multiple therapies were approved to treat AD in children and adolescents since publication of the AAD's 2014 AD guidelines. Objective To provide evidence-based recommendations on the use of topical therapies, phototherapy, and systemic therapies for AD in children and adolescents. Methods A multidisciplinary workgroup conducted a systematic review and applied the GRADE approach for assessing the certainty of evidence and formulating and grading recommendations. Results The workgroup developed 27 evidence-based recommendations on the medical management of pediatric AD. Limitations This analysis is based on the best available evidence at the time it was conducted. Most randomized controlled trials of therapies for AD are of short duration limiting long-term efficacy and safety conclusions. Conclusions We make strong recommendations for the use of moisturizers, topical calcineurin inhibitors, topical corticosteroids, crisaborole ointment, roflumilast cream, ruxolitinib cream, tapinarof cream, dupilumab, tralokinumab, lebrikizumab, nemolizumab with concomitant topical therapy, upadacitinib, abrocitinib, and baricitinib in the treatment of pediatric AD. We make conditional recommendations in favor of bathing, bleach baths, wet dressings, phototherapy, methotrexate, mycophenolate mofetil, azathioprine, and cyclosporine. We conditionally recommend against the use of topical antimicrobials, PUVA phototherapy, and strongly recommend against systemic corticosteroids.
Branding in health care represents a strategic framework that defines organizational identity and aligns stakeholders. In dermatology, it plays a central role in fostering patient trust, strengthening professional credibility, and shaping public perception of the specialty. In early 2020, the American Academy of Dermatology undertook a comprehensive, research-driven rebranding process grounded in qualitative and quantitative methodologies to better understand member perspectives and align its identity with strategic priorities and organizational mission. Foundational research demonstrated strong performance in education and advocacy while identifying gaps in perceived innovation, transparency, and member engagement.
Background While many adults diagnosed with atopic dermatitis (AD) achieve disease control with standard treatments, a subset of patients remains refractory to optimal management. In these cases, misdiagnosis or the presence of concomitant conditions may be contributing to treatment failure. Objective To provide evidence-informed guidance for the diagnostic workup of presumed adult AD unresponsive to optimized treatment. Methods An expert multidisciplinary workgroup applied Grading of Recommendations, Assessment, Development, and Evaluation methodology for issuing guidance on approaching suspected AD refractory to treatment by reviewing the indirect evidence, assessing the balance of benefits and harms, and reaching consensus. Results The workgroup developed a Good Practice Statement on the diagnostic workup of adults with presumed AD unresponsive to therapy. Limitations This guidance is based on indirect evidence and expert consensus, as direct empirical data on diagnostic workup strategies for treatment-resistant AD are lacking. Applicability may vary depending on access to dermatologic and allergy specialist care. Conclusion The Good Practice Statement supports consideration of diagnostic reassessment in cases of presumed AD in adults not responding to optimized treatment.
Background Pediatric atopic dermatitis (AD) is a common, chronic inflammatory skin disorder that significantly impacts the quality of life of affected children and their families. In addition to skin-related symptoms, AD in pediatric patients may be associated with a range of comorbid conditions. Objective To provide evidence-based recommendations on primary prevention of AD and to appraise evidence of the association between AD and comorbidities among pediatric patients. Methods A multidisciplinary workgroup conducted a systematic review and applied the Grading of Recommendations, Assessment, Development, and Evaluation approach for assessing the certainty of evidence and formulating and grading recommendations. Results The workgroup developed 14 evidence-based recommendations on primary prevention of AD and 29 statements on the association between pediatric AD and comorbid conditions. Limitations This analysis is based on the best available evidence at the time it was conducted. This guideline does not make recommendations for screening or management of comorbidities in children with AD. Conclusions We make a conditional recommendation for moisturizing skin care to reduce the occurrence of AD and conditional recommendations against early food introduction, human milk consumption, and probiotic or vitamin D supplementation for the primary prevention of AD. Clinicians should be aware of comorbidities associated with pediatric AD, but further research is needed to optimize screening and/or management of comorbidities.